- (Science Daily via NewsPoints Desk)

Genetic variation behind acute myeloid leukemia treatment success identified - (Science Daily via NewsPoints Desk)

  • Research data published in the journal Clinical Cancer Research reveal that genetic polymorphisms in CD33 affect how patients with acute myeloid leukaemia respond to the anticancer therapy gemtuzumab ozogamicin, Science Daily reported.
  • In the study, Jatinder Lamba and colleagues evaluated three genetic variations of CD33 in paediatric patients that received or did not receive gemtuzumab ozogamicin, determining that a specific genetic variation in CD33 affected the clinical outcome of patients who received the drug.
  • "Understanding how genetics play a role in how drugs work is extremely useful, particularly for a drug like [gemtuzumab ozogamicin] which has shown a very heterogeneous response in [acute myeloid leukaemia] patients," remarked Lamba.
  • "Our hope is that our research could serve as a marker of prognostic significance for clinicians to select the therapy that has the greatest odds of being effective for individual patients based on their CD33 genotype," Lamba added.

To read more NewsPoints articles, click here.